FDA Delays Action On MedImmune's Rezield Despite Negative Panel Vote
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
In a surprise move, FDA has delayed action on MedImmune's Rezield (motavizumab), its second-generation preventive treatment for respiratory syncytial virus, even though the agency already has a vote against approval from an overwhelmingly negative advisory committee review three weeks earlier